AN OPEN-LABEL, SINGLE-ARM, MULTICOHORT, PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF TABELECLEUCEL IN SUBJECTS WITH EPSTEIN-BARR VIRUS-ASSOCIATED DISEASES
This is a multi-cohort, Phase 2, single arm, open label study of tabelecleucel (allogenic EBV-specific T-cell immunotherapy) in patients with EBV+ sarcoma, to include leiomyosarcoma (one of six cohorts). Patients can be newly diagnosed or failed a first-line therapy for EBV+ sarcoma. Newly diagnosed patients should be ineligible to receive standard first-line therapy. Primary objective is to evaluate the clinical benefit of tabelecleucel.
ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT04554914
Sponsor website: www.atarabio.com